A multicenter retrospective analysis on therapeutic plasma exchange in immune thrombocytopenic purpura.
Adult
Aged
Blood Platelets
/ immunology
Female
Humans
Immunoglobulin G
/ immunology
Immunoglobulin M
/ immunology
Immunoglobulins, Intravenous
/ therapeutic use
Male
Middle Aged
Plasma Exchange
/ methods
Purpura, Thrombocytopenic, Idiopathic
/ therapy
Receptors, Thrombopoietin
/ immunology
Retrospective Studies
Rituximab
Splenectomy
Thrombocytopenia
/ therapy
Thrombopoietin
Young Adult
Analysis
Immune thrombocytopenia
Refractory
Therapeutic plasma exchange
Journal
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
ISSN: 1473-0502
Titre abrégé: Transfus Apher Sci
Pays: England
ID NLM: 101095653
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
pubmed:
23
8
2021
medline:
22
2
2022
entrez:
22
8
2021
Statut:
ppublish
Résumé
Immune Thrombocytopenia (ITP) is an autoimmune disease characterized by thrombocytopenia and skin and mucosal bleeding. In patients with an indication for treatment, corticosteroids, intravenous immunoglobulin (IVIg) and anti-D are recommended as the first line, while splenectomy, thrombopoietin receptor agonists or rituximab are recommended second line options. Approximately 10 % of adult patients with ITP fall into the chronic refractory ITP group. Therapeutic plasma exchange (TPE) has generally been tested in patients with refractory ITP, who have failed to respond to conventional treatments, in case of bleeding or prior to surgical interventions. It has been stated that elimination of the antibodies that are held responsible in the pathogenesis of the disease has an effective role in the treatment. In this article, we present the results of 17 patients, who underwent TPE for refractory ITP, together with the literature data.
Identifiants
pubmed: 34419359
pii: S1473-0502(21)00238-X
doi: 10.1016/j.transci.2021.103246
pii:
doi:
Substances chimiques
Immunoglobulin G
0
Immunoglobulin M
0
Immunoglobulins, Intravenous
0
Receptors, Thrombopoietin
0
Rituximab
4F4X42SYQ6
Thrombopoietin
9014-42-0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Pagination
103246Informations de copyright
Copyright © 2021. Published by Elsevier Ltd.